Faraz Ali - 17 Feb 2026 Form 4 Insider Report for Tenaya Therapeutics, Inc. (TNYA)

Role
Chief Executive Officer, Director
Signature
/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact
Issuer symbol
TNYA
Transactions as of
17 Feb 2026
Net transactions value
-$9,557
Form type
4
Filing time
17 Feb 2026, 19:14:17 UTC
Previous filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ali Faraz Chief Executive Officer, Director C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLOOR, SOUTH SAN FRANCISCO /s/ Jennifer Drimmer Rokovich, Attorney-in-Fact 17 Feb 2026 0001667937

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNYA Common Stock Sale $3,762 -5,851 -1.3% $0.6430 452,415 17 Feb 2026 Direct F1, F2, F3
transaction TNYA Common Stock Sale $2,559 -3,979 -0.88% $0.6431 448,436 17 Feb 2026 Direct F2, F4, F5
transaction TNYA Common Stock Sale $3,236 -5,032 -1.1% $0.6430 443,404 17 Feb 2026 Direct F2, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
F2 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F4 Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.
F5 Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F6 Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.
F7 Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.